Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elekta ABEKTAY -2.26%74 Receivables Turnover is 1.26 as of Apr. 2026. GuruFocus rates EKTAY with a GF Score™ of 74/100 and a GF Value™ of $6.51 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Elekta AB ranks worse than 65.84% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Elekta AB's Revenue for the
three
months ended in Apr. 2026 was $514 Mil. Elekta AB's average Accounts Receivable for the
three
months ended in Apr. 2026 was $406 Mil.
Hence, Elekta AB's Receivables Turnover for the
three
months ended in Apr. 2026 was 1.26.
Elekta AB (OTCPK:EKTAY) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Elekta AB Receivables Turnover Related Terms
Elekta AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Elekta AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EKTAY vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Elekta AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elekta AB Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Elekta AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Elekta AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elekta AB (EKTAY) has a Receivables Turnover of 1.26 as of Apr. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Elekta AB and its competitors. According to the industry distribution chart, Elekta AB ranks #534 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 65.8%.
Is Elekta AB's Receivables Turnover too high?
Elekta AB's current Receivables Turnover is 1.26. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Elekta AB's value of 1.26 is 77.1% below this industry median. Based on the distribution chart, Elekta AB ranks #534 out of 811 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Elekta AB has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elekta AB's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Elekta AB ranks #534 out of 811 companies for Receivables Turnover. This places Elekta AB in the lower half of its industry. The industry median Receivables Turnover is 5.51. Elekta AB's value of 1.26 is 77.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elekta AB's current Receivables Turnover of 1.26 is 77.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Elekta AB and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elekta AB's current Receivables Turnover is 1.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elekta AB stock overvalued right now?
Based on GuruFocus' analysis, Elekta AB (EKTAY) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.51, compared to a current price of $4.64 — trading 28.8% below its estimated fair value. The current Receivables Turnover is 1.26 and 77.1% below the Medical Devices & Instruments industry median of 5.51. Elekta AB's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Elekta AB (EKTAY), the current Receivables Turnover is 1.26 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elekta AB (EKTAY) Overvalued in 2026?
Based on GuruFocus' analysis, Elekta AB stock appears to be undervalued.
The current stock price of $4.64 is trading 28.8% below its estimated GF Value™ of $6.51.
GuruFocus considers Elekta AB to be Modestly Undervalued.
Key valuation signals for EKTAY:
Receivables Turnover: 1.26
GF Value™: $6.51 vs. price of $4.64 (28.8% below fair value)
Industry Position: 77.1% below the Medical Devices & Instruments median (#534 of 811)
No single metric tells the full story. See the EKTAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company has an installed base of more than 7,300 linear accelerators, Gamma Knife and Unity platforms, as well as brachytherapy installations. The company's sales are evenly distributed across geographies, with North and South America accounting for 29%; Europe, the Middle East, and Africa accounting for 37%; and the Asia-Pacific contributing the remainder.
74GF Score
Get the complete analysis for EKTAY
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EKTAY has been successfully added to your 
